Initial AX-0810 data show no safety signals after 4 weeks of dosing and pharmacokinetics consistent with non-clinical data; Phase 1 enrollment and dosing in healthy volunteers ongoing with target ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback